Inventage Lab, a South Korean drug delivery platform company, presented new data at the American Diabetes Association (ADA) Scientific Sessions supporting the development of long-acting obesity therapies based on semaglutide and tirzepatide. The findings highlight the potential of its proprietary microfluidics-based platform to create once-monthly injectable formulations, which could reshape supply-chain opportunities for distributors and clinics seeking differentiated GLP-1 products.
Data Highlights
At the 84th ADA Scientific Sessions in New Orleans, Inventage Lab released research on two candidates: IVL3021, a once-monthly semaglutide-based long-acting injectable (LAI), and IVL3024, a next-generation tirzepatide-based LAI. In a diet-induced obesity rat model, IVL3021 demonstrated dose-dependent weight loss with a single monthly injection, comparable to repeated weekly dosing with Wegovy. Body composition analysis showed significant fat mass reduction, smaller adipocyte size, and improvements in liver enzyme levels and triglycerides, suggesting potential benefits for fatty liver disease.
Platform Technology
The studies were enabled by Inventage Lab's proprietary "IVL-DrugFluidic" platform, a microfluidics-based technology that achieves high peptide drug loading (up to 50%) and encapsulation efficiency (over 90%) with uniform particle-size distribution. This platform supports the development of long-acting formulations for multi-target GLP-1 and amylin-based obesity therapies, addressing both efficacy and maintenance treatment needs.
Regulatory and Channel Signals
Inventage Lab plans to advance clinical development of IVL3021 within this year and is collaborating with partners to develop long-acting formulations of various obesity therapies. The company aims to accelerate commercialization discussions with global pharmaceutical companies during BIO USA 2026. For overseas buyers, this signals potential new supply-chain entrants offering differentiated LAI products that could complement existing GLP-1 portfolios.
Sourcing Context
Headquartered in Seongnam, Gyeonggi Province, South Korea, Inventage Lab is positioning itself as a contract development and manufacturing organization (CDMO) partner for peptide-based obesity therapies. Its platform technology could enable distributors and clinics to access long-acting injectables with reduced dosing frequency, potentially improving patient compliance and clinic workflow. Buyers should monitor clinical progress and partnership announcements for sourcing opportunities.
Source: Read the original report | Published: June 08, 2026